AGIO
Price
$33.65
Change
+$0.94 (+2.87%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
1.95B
35 days until earnings call
ZYME
Price
$12.36
Change
-$0.35 (-2.75%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
861.98M
Interact to see
Advertisement

AGIO vs ZYME

Header iconAGIO vs ZYME Comparison
Open Charts AGIO vs ZYMEBanner chart's image
Agios Pharmaceuticals
Price$33.65
Change+$0.94 (+2.87%)
Volume$3.52K
Capitalization1.95B
Zymeworks
Price$12.36
Change-$0.35 (-2.75%)
Volume$18.82K
Capitalization861.98M
AGIO vs ZYME Comparison Chart in %
Loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGIO vs. ZYME commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a Buy and ZYME is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (AGIO: $33.65 vs. ZYME: $12.37)
Brand notoriety: AGIO and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 49% vs. ZYME: 71%
Market capitalization -- AGIO: $1.95B vs. ZYME: $861.98M
AGIO [@Biotechnology] is valued at $1.95B. ZYME’s [@Biotechnology] market capitalization is $861.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 1 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • AGIO’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, both AGIO and ZYME are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 4 TA indicator(s) are bullish while ZYME’s TA Score has 5 bullish TA indicator(s).

  • AGIO’s TA Score: 4 bullish, 5 bearish.
  • ZYME’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ZYME is a better buy in the short-term than AGIO.

Price Growth

AGIO (@Biotechnology) experienced а -5.21% price change this week, while ZYME (@Biotechnology) price change was -2.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

AGIO is expected to report earnings on Jul 31, 2025.

ZYME is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGIO($1.95B) has a higher market cap than ZYME($862M). AGIO YTD gains are higher at: 2.404 vs. ZYME (-15.505). ZYME has higher annual earnings (EBITDA): -95.45M vs. AGIO (-434.71M). AGIO has more cash in the bank: 893M vs. ZYME (265M). ZYME has less debt than AGIO: ZYME (18.5M) vs AGIO (52.9M). ZYME has higher revenues than AGIO: ZYME (93.4M) vs AGIO (37M).
AGIOZYMEAGIO / ZYME
Capitalization1.95B862M226%
EBITDA-434.71M-95.45M455%
Gain YTD2.404-15.505-16%
P/E Ratio2.92N/A-
Revenue37M93.4M40%
Total Cash893M265M337%
Total Debt52.9M18.5M286%
FUNDAMENTALS RATINGS
AGIO vs ZYME: Fundamental Ratings
AGIO
ZYME
OUTLOOK RATING
1..100
7872
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1795
PRICE GROWTH RATING
1..100
5145
P/E GROWTH RATING
1..100
8265
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (40) in the Biotechnology industry is in the same range as ZYME (45) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew similarly to ZYME’s over the last 12 months.

AGIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ZYME (100) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew similarly to ZYME’s over the last 12 months.

AGIO's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for ZYME (95) in the Pharmaceuticals Major industry. This means that AGIO’s stock grew significantly faster than ZYME’s over the last 12 months.

ZYME's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as AGIO (51) in the Biotechnology industry. This means that ZYME’s stock grew similarly to AGIO’s over the last 12 months.

ZYME's P/E Growth Rating (65) in the Pharmaceuticals Major industry is in the same range as AGIO (82) in the Biotechnology industry. This means that ZYME’s stock grew similarly to AGIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIOZYME
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 23 days ago
76%
Bullish Trend 23 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NEWFX88.540.90
+1.03%
American Funds New World A
PIEQX18.49N/A
N/A
T. Rowe Price International Eq Index
EQIIX13.05N/A
N/A
Allspring Emerging Markets Eq Advtg Inst
MGGPX37.13N/A
N/A
Morgan Stanley Inst Global Opp A
STRBX19.04N/A
N/A
Sterling Capital Behav Sm Cp Val Eq R6

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with LGND. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then LGND could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
+2.87%
LGND - AGIO
51%
Loosely correlated
-0.03%
ZYME - AGIO
49%
Loosely correlated
-2.68%
CRNX - AGIO
47%
Loosely correlated
-1.38%
VRDN - AGIO
46%
Loosely correlated
-1.02%
AXON - AGIO
45%
Loosely correlated
+2.40%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with ABCL. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
-2.68%
ABCL - ZYME
49%
Loosely correlated
-1.58%
AGIO - ZYME
49%
Loosely correlated
+2.87%
CRNX - ZYME
47%
Loosely correlated
-1.38%
IDYA - ZYME
47%
Loosely correlated
+1.27%
ANNX - ZYME
47%
Loosely correlated
+2.51%
More